Description
Ilexhainanoside D is the main triterpenoid saponin extracted from Ilex hainanensis Merr., and the combination of Ilexhainanoside D and ilexsaponin A1 has anti-inflammation effect.
Product information
CAS Number: 1137648-52-2
Molecular Weight: 664.82
Formula: C36H56O11
Chemical Name: (3S,4R,4aR,6aR,6bS,8aR,12S,12aS,14aR,14bR)-3,12-dihydroxy-4,6a,6b,11,11,14b-hexamethyl-8a-({[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicene-4-carboxylic acid
Smiles: CC1(C)CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)[C@@](C)([C@@H]5CC[C@@]34C)C(O)=O)[C@@H]2[C@@H]1O)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
InChiKey: PWXPWSCNXVCOCA-YFIGHCCUSA-N
InChi: InChI=1S/C36H56O11/c1-31(2)13-15-36(30(45)47-28-26(41)25(40)24(39)19(17-37)46-28)16-14-33(4)18(23(36)27(31)42)7-8-20-32(3)11-10-22(38)35(6,29(43)44)21(32)9-12-34(20,33)5/h7,19-28,37-42H,8-17H2,1-6H3,(H,43,44)/t19-,20-,21-,22+,23-,24-,25+,26-,27+,28+,32-,33-,34-,35-,36+/m1/s1
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vivo:
The combination of Ilexhainanoside D and Ilexsaponin A (60, 120 or 240 mg/kg; for 8 weeks) treatment significantly reduces the severity of non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet in a dose-dependent manner. The combination of Ilexhainanoside D and Ilexsaponin A treatment decreases the ratio of Firmicutes/Bacteroidetes, reduces the relative abundance of Desulfovibrio and increases the relative abundance of Akkermansia. The intestinal barrier is improved as evidenced by the upregulation of the expression of zonula occludens-1 (ZO-1) and occludin in the ileum. The combination of Ilexhainanoside D and Ilexsaponin A treatment reduces the entry of LPS into the circulation and decreases the hepatic gene expression levels of proinflammatory cytokines.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.